艾美疫苗(06660.HK)反覆彈19% 確認H股禁售期昨天流通及營運正常
艾美疫苗(06660.HK)就股價和成交大幅波動發聲明確認營運正常,以及表示H股一年禁售期上周五(6日)屆滿並於昨天(9日)開始流通交易。該股繼昨天反覆急挫51%曾低見10.2元上市新低兼成交1,780萬股創紀錄成交後,今天反覆回升,高低見13.78元/10.9元,現報13.2元,反覆彈19%,成交已有1,445萬股,涉資1.8億元。
艾美就股價及成交量不尋常波動聲明,確認集團的營運、財務和現有產品銷售情況均正常,且在研管線疫苗的研發均按計劃正常推進;及公司持有H股權益的董事均未出售或以其它方式處置所持H股。同時,公司上市前已發行的H股一年禁售期已於10月6日屆滿,並於昨天於聯交所開始流通交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.